BMY's ulcerative colitis drug fails clinical trials. If only we knew of a company that had an anti-inflammatory, antibiotic drug that might help diseases of the gut.....

Quote:

---

Bristol Myers Squibb’s deucravacitinib, seeking to become the first TYK2 drug approved, flopped a key Phase II test in ulcerative colitis, failing to spur clinical remission at three months and missing key secondary endpoints at an interim check-in, the drug giant admitted Thursday.

https://endpts.com/bristol-myers-tyk2-drug-bo...g-on-deck/

---